5:32 PM
 | 
Dec 19, 2012
 |  BC Extra  |  Clinical News

Victoza/Tresiba combo meets diabetes endpoint

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) said IDegLira plus metformin met the primary endpoint of reducing HbA1c from baseline to week 26 vs. Tresiba plus metformin in the Phase IIIa DUAL II trial to treat Type II diabetes. IDegLira plus metformin led to a 1.9%...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >